Michael Choi

Title(s)Associate Clinical Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Overview 

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Improving the outlook for TP53-aberrant CLL. Blood. 2021 Nov 11; 138(19):1785-1786. Choi MY. PMID: 34762129.
      View in: PubMed   Mentions:
    2. Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy. Blood. 2021 Sep 09; 138(10):836-846. Ma S, Seymour JF, Brander DM, Kipps TJ, Choi MY, Anderson MA, Humphrey K, Al Masud A, Pesko J, Nandam R, Salem AH, Chyla B, Arzt J, Jacobson A, Kim SY, Roberts AW. PMID: 34115103.
      View in: PubMed   Mentions:    Fields:    
    3. Targeted Therapy in Chronic Lymphocytic Leukemia. Cancer J. 2019 Nov/Dec; 25(6):378-385. Kipps TJ, Choi MY. PMID: 31764118; PMCID: PMC7039327.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    4. Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia. Blood. 2019 09 26; 134(13):1084-1094. Chen Y, Chen L, Yu J, Ghia EM, Choi MY, Zhang L, Zhang S, Sanchez-Lopez E, Widhopf GF, Messer K, Rassenti LZ, Jamieson C, Kipps TJ. PMID: 31409670; PMCID: PMC6764264.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    5. SOHO State of the Art Updates and Next Questions: The Conundrum in Assessing the Therapy Response of Patients With Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):321-325. Choi MY, Wang HY, Kipps TJ. PMID: 31204237.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels. Haematologica. 2020 01; 105(1):e22-e25. Lujan JV, Lengerke-Diaz PA, Jacobs C, Moreno-Cortes EF, Ramirez-Segura CA, Choi MY, McCarthy C, Heinen A, Kipps TJ, Castro JE. PMID: 31048356; PMCID: PMC6939526.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    7. Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials. Cancers (Basel). 2018 Dec 21; 11(1). Galanina N, Bejar R, Choi M, Goodman A, Wieduwilt M, Mulroney C, Kim L, Yeerna H, Tamayo P, Vergilio JA, Mughal TI, Miller V, Jamieson C, Kurzrock R. PMID: 30583461; PMCID: PMC6356731.
      View in: PubMed   Mentions: 5  
    8. JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis. . 2018 08 03; 19(8):664-668. Choi MY, Kato S, Wang HY, Lin JH, Lanman RB, Kurzrock R. PMID: 29565699; PMCID: PMC6067874.
      View in: PubMed   Mentions: Translation:Humans
    9. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell Stem Cell. 2018 Jun 01; 22(6):951-959.e3. Choi MY, Widhopf GF, Ghia EM, Kidwell RL, Hasan MK, Yu J, Rassenti LZ, Chen L, Chen Y, Pittman E, Pu M, Messer K, Prussak CE, Castro JE, Jamieson C, Kipps TJ. PMID: 29859176; PMCID: PMC7001723.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCellsCTClinical Trials
    10. BRAF mutation as a novel driver of eosinophilic cystitis. . 2017 Sep 02; 18(9):655-659. Choi MY, Tsigelny IF, Boichard A, Skjevik ÅA, Shabaik A, Kurzrock R. PMID: 28829677; PMCID: PMC5663411.
      View in: PubMed   Mentions: 1  Translation:HumansCells
    11. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. J Hematol Oncol. 2017 05 19; 10(1):112. Kashyap MK, Amaya-Chanaga CI, Kumar D, Simmons B, Huser N, Gu Y, Hallin M, Lindquist K, Yafawi R, Choi MY, Amine AA, Rassenti LZ, Zhang C, Liu SH, Smeal T, Fantin VR, Kipps TJ, Pernasetti F, Castro JE. PMID: 28526063; PMCID: PMC5438492.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    12. Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies. JCO Precis Oncol. 2017 06; 1. Goodman AM, Choi M, Wieduwilt M, Mulroney C, Costello C, Frampton G, Miller V, Kurzrock R. PMID: 28681041; PMCID: PMC5495179.
      View in: PubMed   Mentions: 10  
    13. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017 Feb; 18(2):230-240. Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW. PMID: 28089635; PMCID: PMC5316338.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCTClinical Trials
    14. How Do Targeted Therapies Change the Management of Indolent Lymphomas? Oncology (Williston Park). 2016 09 15; 30(9):859-60. Choi MY, Kipps TJ. PMID: 27633418.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptor. Best Pract Res Clin Haematol. 2016 03; 29(1):40-53. Choi MY, Kashyap MK, Kumar D. PMID: 27742071.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    16. ATM Mutations in Cancer: Therapeutic Implications. . 2016 08; 15(8):1781-91. Choi M, Kipps T, Kurzrock R. PMID: 27413114.
      View in: PubMed   Mentions: 118  Translation:HumansAnimals
    17. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget. 2016 Jan 19; 7(3):2809-22. Kashyap MK, Kumar D, Jones H, Amaya-Chanaga CI, Choi MY, Melo-Cardenas J, Ale-Ali A, Kuhne MR, Sabbatini P, Cohen LJ, Shelat SG, Rassenti LZ, Kipps TJ, Cardarelli PM, Castro JE. PMID: 26646452; PMCID: PMC4823073.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    18. Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15 Suppl:S167-9. Choi MY, Widhopf GF, Wu CC, Cui B, Lao F, Sadarangani A, Cavagnaro J, Prussak C, Carson DA, Jamieson C, Kipps TJ. PMID: 26297272; PMCID: PMC4548279.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    19. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML. . 2015 Jul; 14(7):1650-60. Pereira DS, Guevara CI, Jin L, Mbong N, Verlinsky A, Hsu SJ, Aviña H, Karki S, Abad JD, Yang P, Moon SJ, Malik F, Choi MY, An Z, Morrison K, Challita-Eid PM, Doñate F, Joseph IB, Kipps TJ, Dick JE, Stover DR. PMID: 25934707; PMCID: PMC4557793.
      View in: PubMed   Mentions: 29  Translation:HumansAnimalsCells
    20. Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies. J Med Chem. 2014 Jun 26; 57(12):5085-93. Stout EP, Choi MY, Castro JE, Molinski TF. PMID: 24673739; PMCID: PMC4079331.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    21. Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J. 2012 Sep-Oct; 18(5):404-10. Choi MY, Kipps TJ. PMID: 23006944; PMCID: PMC3461329.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    22. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011 Aug 09; 108(32):13253-7. Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA. PMID: 21788521; PMCID: PMC3156152.
      View in: PubMed   Mentions: 136     Fields:    Translation:HumansCells
    Michael's Networks
    Concepts (146)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (17)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version v3.1.0-868-g8ba5679c on PROFILES-PWEB02.

    Copyright © The Regents of the University of California